QMBlog Content
Discover More:
// March 01, 2024
Innovating for Individual Care: The Impact of USP on Personalized Medicine...
In 2022, personalized medicines (PM) made up more than 34% of new therapeutics approved by the Food and Drug Administration (FDA).
// January 04, 2024
Prioritizing Quality Across the Manufacturing Eco-System in India...
India is often referred to as the ‘pharmacy of the world’ and is undeniably the leading manufacturing hub for many of the world’s most essential medicines.
// December 08, 2023
Revisiting the Landscape of Potential Nitrosamines in Pharmaceuticals using CPCA fram...
Quality Matters recently sat down with USP Principal Scientist Naiffer Romero, who has teamed up with researchers at LHASA Limited, AstraZeneca, Sai Life Sciences and Merck for collaborative research on nitrosamine impurities. In Part One of this series, we discussed the new research. Here’s Part Two.
// November 27, 2023
Revisiting the Landscape of Potential Nitrosamines in Pharmaceuticals using CPCA fram...
USP’s Naiffer Romero has teamed up with researchers at LHASA Limited, AstraZeneca, Sai Life Sciences and Merck for collaborative research on nitrosamines impurities that was published this month in the Journal of Pharmaceutical Sciences. Quality Matters recently sat down with Romero, who leads USP’s Nitrosamines Exchange, to learn more about the new research and what it means for the field.